Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Amicus Therapeutics Uk Ltd

Home Clinical Trial Sponsors and OrganizationsAmicus Therapeutics Uk Ltd

Amicus Therapeutics Uk Ltd

Fridtjof Nansens vei 19, Oslo, Norway

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

4 active

Approvals

1

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

4

100.0%

Trial Status Distribution

Active, not recruiting

4

100.0%

Clinical Trials

Trials sponsored by this organization (4)

AN OPEN-LABEL STUDY OF THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF 12-MONTH TREATMENT WITH MIGALASTAT IN PEDIATRIC SUBJECTS (AGED 12 TO <18 YEARS) WITH FABRY DISEASE AND AMENABLE GLA VARIANTS

Active, not recruiting

Oct 202020 participants

ASPIRE Pediatric Fabry Study

Active, not recruiting

Apr 201922 participants

AN OPEN-LABEL STUDY OF THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF 12-MONTH TREATMENT WITH MIGALASTAT IN PEDIATRIC SUBJECTS (AGED 12 TO <18 YEARS) WITH FABRY DISEASE AND AMENABLE GLA VARIANTS

Active, not recruiting

Mar 201920 participants

ASPIRE Paediatric Fabry Study

Active, not recruiting

Mar 201920 participants

Approvals

Approvals by Agency

EMC

Electronic Medicines Compendium

1

Approvals

Recent Approvals

Pombiliti 105 mg powder for concentrate for solution for infusion

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals1
News

Back to Organizations